Thanks to a confluence of favorable factors, immuno-oncology’s capital markets are booming, having been flooded by venture capitalist investments that are driving development. The result: the market is seeing fewer deals, but on a larger scale, and with a shortened path to an exit. Understand the trends for immuno-oncology transactions, investigate institutional investor activity in the area, and gain a view into the exit landscape for investors as you gather key takeaways for investment in the IO area with this insightful article from In Vivo.
This product is an industry newsletter. Each license type allows a set number of users to access the newsletter for the length of the subscription period. This product is an industry newsletter. This is a single user license, allowing one user access to the product. The product is a PDF. This product is an industry newsletter. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net